Striatal molecular alterations in HD gene carriers: A systematic review and meta-analysis of PET studies

TY - JOUR

T1 - Striatal molecular alterations in HD gene carriers

T2 - A systematic review and meta-analysis of PET studies

AU - Niccolini, Flavia

AU - Pagano, Gennaro

AU - Fusar-Poli, Paolo

AU - Wood, Andrew

AU - Mrzljak, Ladislav

AU - Sampaio, Cristina

AU - Politis, Marios

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background Over the past years, positron emission tomography (PET) imaging studies have investigated striatal molecular changes in premanifest and manifest Huntington's disease (HD) gene expansion carriers (HDGECs), but they have yielded inconsistent results. Objective To systematically examine the evidence of striatal molecular alterations in manifest and premanifest HDGECs as measured by PET imaging studies. Methods MEDLINE, ISI Web of Science, Cochrane Library and Scopus databases were searched for articles published until 7 June 2017 that included PET studies in manifest and premanifest HDGECs. Meta-analyses were conducted with random effect models, and heterogeneity was addressed with I 2 index, controlling for publication bias and quality of study. The primary outcome was the standardised mean difference (SMD) of PET uptakes in the whole striatum, caudate and putamen in manifest and premanifest HDGECs compared with healthy controls (HCs). Results Twenty-four out of 63 PET studies in premanifest (n=158) and manifest (n=191) HDGECs and HCs (n=333) were included in the meta-analysis. Premanifest and manifest HDGECs showed significant decreases in dopamine D 2 receptors in caudate (SMD=-1.233, 95% CI-1.753 to-0.713, p<0.0001; SMD=-5.792, 95% CI-7.695 to-3.890, p<0.0001) and putamen (SMD=-1.479, 95% CI-1.965 to-0.992, p<0.0001; SMD=-5.053, 95% CI-6.558 to-3.549, p<0.0001), in glucose metabolism in caudate (SMD=-0.758, 95% CI-1.139 to-0.376, p<0.0001; SMD=-3.738, 95% CI-4.880 to-2.597, p<0.0001) and putamen (SMD=-2.462, 95% CI-4.208 to-0.717, p=0.006; SMD=-1.650, 95% CI-2.842 to-0.458, p<0.001) and in striatal PDE10A binding (SMD=-1.663, 95% CI-2.603 to-0.723, p=0.001; SMD=-2.445, 95% CI-3.371 to-1.519, p<0.001). Conclusions PET imaging has the potential to detect striatal molecular changes even at the early premanifest stage of HD, which are relevant to the neuropathological mechanisms underlying the development of the disease.

AB - Background Over the past years, positron emission tomography (PET) imaging studies have investigated striatal molecular changes in premanifest and manifest Huntington's disease (HD) gene expansion carriers (HDGECs), but they have yielded inconsistent results. Objective To systematically examine the evidence of striatal molecular alterations in manifest and premanifest HDGECs as measured by PET imaging studies. Methods MEDLINE, ISI Web of Science, Cochrane Library and Scopus databases were searched for articles published until 7 June 2017 that included PET studies in manifest and premanifest HDGECs. Meta-analyses were conducted with random effect models, and heterogeneity was addressed with I 2 index, controlling for publication bias and quality of study. The primary outcome was the standardised mean difference (SMD) of PET uptakes in the whole striatum, caudate and putamen in manifest and premanifest HDGECs compared with healthy controls (HCs). Results Twenty-four out of 63 PET studies in premanifest (n=158) and manifest (n=191) HDGECs and HCs (n=333) were included in the meta-analysis. Premanifest and manifest HDGECs showed significant decreases in dopamine D 2 receptors in caudate (SMD=-1.233, 95% CI-1.753 to-0.713, p<0.0001; SMD=-5.792, 95% CI-7.695 to-3.890, p<0.0001) and putamen (SMD=-1.479, 95% CI-1.965 to-0.992, p<0.0001; SMD=-5.053, 95% CI-6.558 to-3.549, p<0.0001), in glucose metabolism in caudate (SMD=-0.758, 95% CI-1.139 to-0.376, p<0.0001; SMD=-3.738, 95% CI-4.880 to-2.597, p<0.0001) and putamen (SMD=-2.462, 95% CI-4.208 to-0.717, p=0.006; SMD=-1.650, 95% CI-2.842 to-0.458, p<0.001) and in striatal PDE10A binding (SMD=-1.663, 95% CI-2.603 to-0.723, p=0.001; SMD=-2.445, 95% CI-3.371 to-1.519, p<0.001). Conclusions PET imaging has the potential to detect striatal molecular changes even at the early premanifest stage of HD, which are relevant to the neuropathological mechanisms underlying the development of the disease.

KW - huntington's disease gene carriers

KW - manifest

KW - PET

KW - premanifet

UR - http://www.scopus.com/inward/record.url?scp=85048301562&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2017-316633

DO - 10.1136/jnnp-2017-316633

M3 - Review article

AN - SCOPUS:85048301562

SN - 0022-3050

VL - 89

SP - 185

EP - 196

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

IS - 2

ER -